Archive for September 2024
Firebrick Consultant to drive Pharmacy Distribution in Singapore
Firebrick Pharma (ASX:FRE) is pleased to announce that it has executed a consulting agreement (Agreement) with Keith Shortall, a former senior executive of Johnson & Johnson Consumer Health Asia-Pacific (J&J Consumer Health APAC). The primary goal of the Agreement is to establish pharmacy distribution for Nasodine in Singapore. Secondary objectives include evaluating potential distribution to…
Nasodine European Marketing Application filed and passed validation
Firebrick Pharma (ASX:FRE) is pleased to announce that it has filed a Marketing Authorisation Application (“MAA”) in Europe for the approval of Nasodine® Nasal Spray as a nasal antiseptic. The MAA has successfully passed validation and has now entered the evaluation phase. The application was filed via a decentralised procedure, where one EU member state,…